Public deck

Merck: Keytruda scale still has to bridge the patent and pipeline test

Merck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.